JoseA.CortesMD

PubMed

• 1 citations
  Implementing Rounding Checklists in a Pediatric Oncologic Intensive Care Unit.
  Mary Katherine Gardner, Patricia J Amado, Muhummad Usman Baig, Avis Harden, Linette J Ewing, Shehla Razvi, Jose A Cortes, Rodrigo Mejia, Demetrios Petropoulos, Priti T...> ;Children. 2022 Apr 18
• Achievement of a Negative Minimal Residual Disease State After Hypomethylating Agent Therapy in Older Patients with AML Reduces the Risk of Relapse
  J Jorgensen, T Kadia, C D DiNardo, E J Jabbour, H Kantarjian, P Bose, M Konopleva, G Borthakur, N Pemmaraju, J Cortes> ;Nature. 2017 Sep 19
• Concordant Bone Marrow Involvement of Diffuse Large B-cell Lymphoma Represents a Distinct Clinical and Biological Entity in the Era of Immunotherapy
  K H Young, J Wang, W Tam, E D Hsi, J N Winter, J Cortes, L Fayad, L J Medeiros, Y Li, G Bhagat, R Z Orlowski, H Kantarjian> ;Nature. 2017 Jul 27
• A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
  Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Es...> ;Leukemia. 2016-11-18
• Research needs in breast cancer.
  Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA> ;Ann. Oncol.. 2016-11-09
• Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic...
  Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, ...> ;Ann. Oncol.. 2016-11-01
• PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
  Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin ...> ;Leukemia. 2016-10-18
• New drugs in acute myeloid leukemia.
  Kadia TM, Ravandi F, Cortes J, Kantarjian H> ;Ann. Oncol.. 2016-05-01
• Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
  Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gr...> ;Ann. Oncol.. 2016-03-01
• A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
  Daver, N.,Kantarjian, H.,Ravandi, F.,Estey, E.,Wang, X.,Garcia-Manero, G.,Jabbour, E.,Konopleva, M.,O'Brien, S.,Verstovsek, S.,Kadia, T.,Dinardo, C.,Pierce, S.,Huang, ...> ;Leukemia. 2015 Sep 15
• Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists.
  Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E> ;Ann. Oncol.. 2015-07-01
• 57 citations
  Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases.
  Andrea Hayes-Jordan, Holly Green, Heather Lin, Pascal Owusu-Agyemang, Rodrigo Mejia, Regina Okhuysen-Cawley, Jose Antonio Cortes, Nancy E. Fitzgerald, Mary Frances McA...> ;Annals of Surgical Oncology. 2015 Jan 7
• Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
  De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard F, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Taberne...> ;Ann. Oncol.. 2014-09-01
• Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results fro...
  Swain SM, Baselga J, Miles D, Im Y, Quah C, Lee LF, Cortés J> ;Ann. Oncol.. 2014-06-01
• Survival of women with inflammatory breast cancer: a large population-based study†.
  Dawood, S.,Lei, X.,Dent, R.,Gupta, S.,Sirohi, B.,Cortes, J.,Cristofanilli, M.,Buchholz, T.,Gonzalez-Angulo, A. M.> ;Ann. Oncol.. 2014 Mar 29
• Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
  Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M> ;Ann. Oncol.. 2014-03-01
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
  Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J> ;Ann. Oncol.. 2014-03-01
• Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.
  Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E> ;Leukemia. 2014-02-01
• Expression of PD-L1, PD-L2, PD-1 and CTLA4 in Myelodysplastic Syndromes Is Enhanced by Treatment with Hypomethylating Agents
  H Kantarjian, S Parmar, J Cortes> ;Nature. 2013 Nov 26
• First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.
  Miles DW, Diéras V, Cortés J, Duenne A, Yi J, O'Shaughnessy J> ;Ann. Oncol.. 2013-11-01
• The Combination of Hyper-CVAD plus Nelarabine as Frontline Therapy in Adult T Cell Acute Lymphoblastic Leukemia (T-ALL) and T-lymphoblastic Lymphoma (LL)-MD Anderson C...
  J Burger, N Pemmaraju, E Jabbour, S Faderl, M Konopleva, H Kantarjian, D Thomas, J Cortes, T Kadia, G Borthakur> ;Nature. 2013 Oct 26
• Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
  Cortés J, Baselga J, Im Y, Im S, Pivot X, Ross G, Clark E, Knott A, Swain SM> ;Ann. Oncol.. 2013-10-01
• Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
  Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G> ;Leukemia. 2013-10-01
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positi...
  Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y, Ratnayake J, McNally V, Ross G, Cortés J> ;Ann. Oncol.. 2013-09-01
• Management of the axilla in early breast cancer patients in the genomic era.
  Oliveira M, Cortés J, Bellet M, Balmaña J, De Mattos-Arruda L, Gómez P, Muñoz E, Ortega V, Pérez J, Saura C, Vidal M, Rubio IT, Di Cosimo S> ;Ann. Oncol.. 2013-05-01
• Join now to see all